Table 2 Blood tests of the 79 patients and comparisons between patients treated with tocilizumab + Std therapy and those treated with Std therapy alone
From: Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
Overall population | Tocilizumab + Std therapy | Std therapy | p value | |
|---|---|---|---|---|
pH, mean ± SD | ||||
At admission | 7.45 ± 0.05 | 7.46 ± 0.5 | 7.45 ± 0.05 | 0.66 |
At 72 h | 7.44 ± 0.07 | 7.44 ± 0.03 | 7.43 ± 0.1 | 0.07 |
At 7 days | 7.45 ± 0.04 | 7.44 ± 0.04 | 7.46 ± 0.03 | 0.05 |
pO2 (mmHg), mean ± SD | ||||
At admission | 67.4 ± 20.3 | 67.1 ± 16.9 | 67.7 ± 23.8 | 0.66 |
At 72 h | 85.7 ± 29.9 | 85.2 ± 18.5 | 86.1 ± 39.8 | 0.4 |
At 7 days | 100.8 ± 42.7 | 104 ± 42.9 | 95.9 ± 43.1 | 0.5 |
pCO2 (mmHg), mean ± SD | ||||
At admission | 36.5 ± 6.2 | 36.9 ± 5.5 | 36 ± 7 | 0.3 |
At 72 h | 40.7 ± 11.1 | 40.2 ± 4.8 | 41.4 ± 15.6 | 0.4 |
At 7 days | 40 ± 5.9 | 39.4 ± 4.9 | 40.8 ± 7.2 | 0.5 |
pO2/FiO2 ratio (mmHg), mean ± SD | ||||
At admission | 120.1 ± 41.6 | 117.8 ± 34.4 | 122.8 ± 48.9 | 0.8 |
At 72 h | 155.6 ± 78.6 | 143.8 ± 53 | 169.6 ± 100.2 | 0.6 |
At 7 days | 191 ± 86.8 | 186.2 ± 78.5 | 198.1 ± 99.3 | 0.8 |
Leukocytes (109/L), mean ± SD | ||||
At admission | 6.42 ± 2.68 | 6.2 ± 2.7 | 7.2 ± 2.4 | 0.1 |
At 72 h | 8.1 ± 3 | 8.2 ± 3.2 | 7.6 ± 2.2 | 0.9 |
At 7 days | 8.3 ± 3.9 | 8.2 ± 4.1 | 8.5 ± 3.3 | 0.8 |
Neutrophils (109 / L), mean ± SD | ||||
At admission | 4.77 ± 1.89 | 4.6 ± 1.9 | 5.8 ± 1.7 | 0.07 |
At 72 h | 6.8 ± 3 | 6.9 ± 3.1 | 6.4 ± 2.6 | 0.6 |
At 7 days | 6.5 ± 4.2 | 6.4 ± 4.4 | 6.7 ± 3.6 | 0.7 |
Lymphocytes (109 / L), mean ± SD | ||||
At admission | 0.8 ± 0.35 | 0.8 ± 0.4 | 0.9 ± 0.3 | 0.6 |
At 72 h | 0.8 ± 0.5 | 0.8 ± 0.5 | 0.8 ± 0.5 | 0.9 |
At 7 days | 1.2 ± 0.5 | 1.2 ± 0.6 | 1.2 ± 0.4 | 0.8 |
D-dimer (ng/dl), mean ± SD | ||||
At admission | 774.5 ± 917 | 775 ± 957.8 | – | NA |
At 72 h | 6388.2 ± 8143.4 | 5388.3 ± 8143.4 | – | NA |
At 7 days | 2602.7 ± 2861.1 | 2602.7 ± 2861.1 | – | NA |
Ferritin (ng/ml), mean ± SD | ||||
At admission | 688.9 ± 683.6 | 652.9 ± 721.6 | – | NA |
At 72 h | 1758.9 ± 1545.7 | 1906 ± 1603 | 830 ± 415 | 0.3 |
At 7 days | 1137.9 ± 881.6 | 1194 ± 903.4 | 577 ± 349.3 | 0.4 |
CRP (mg/dl), mean ± SD | ||||
At admission | 11.9 ± 7.2 | 11.2 ± 7 | 14.3 ± 7.6 | 0.2 |
At 72 h | 8.5 ± 9.5 | 6.4 ± 6.5 | 17.2 ± 14.9 | 0.02 |
At 7 days | 4.5 ± 8.4 | 2.3 ± 4.9 | 13.3 ± 13.5 | 0.001 |
LDH (U/l), mean ± SD | ||||
At admission | 687.7 ± 244.6 | 700.5 ± 250.5 | 534 ± 24.4 | 0.2 |
At 72 h | 745.3 ± 320.3 | 757 ± 314 | 701 ± 361.7 | 0.2 |
At 7 days | 682.3 ± 326.5 | 693.1 ± 334.9 | 633.3 ± 309.1 | 0.7 |
IL-6 (pg/ml), mean ± SD | ||||
At admission | 147.2 ± 180.4 | 145.9 ± 190.1 | – | NA |
At 72 h | 656.4 ± 878.9 | 656.4 ± 878.9 | – | NA |
At 7 days | 623.2 ± 1217.4 | 623.2 ± 1217.4 | – | NA |